Decision Diagnostics, Corp. (OTCBB:DECN) Takes Another Break, Down 15%
It seems the stock of Decision Diagnostics, Corp. (OTCBB:DECN), formerly InstaCare Corp., is getting tired of its wild run. DECN slid down more than 15% to 67 cents, on dollar volumes of $386,000. The company so far has no updates on the court struggle with Johnson&Johnson Company, as it tries to spread wider its lower-price glucose testing strips. If successful, DECN could secure significant revenues. 
Currently, DECN is not seeing a promotion beyond a series of press releases, plus the tension ahead of a court decision. So it’s up to the markets to regulate a price that would reflect the new business position of the company. 
DECN is currently priced at just $14 million, a relatively small amount compared to other penny stocks that make more noise. With just 21 million shares outstanding and daily trading hardly exceeding 500K shares, DECN is still an undiscovered opportunity. True, the stock lost money for longer-term investors from years back, but now there is the hope of a recovery, despite the setbacks in the last two days.
Currently, DECN lines up with the following financial strengths and weaknesses:
- $160 thousand cash
- $3.5 million total current assets
- $4 million total current liabilities
- $377 thousand revenues
- $1,7 million net loss
With all of those, DECN resembles other pharmaceutical stocks that are still awaiting to become a market hit of an in-demand drug. At least DECN has a product at the ready, if it breaks through the resistance of test-strip and glucometer vendors, which are all giant businesses.
Another returning ticker is Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS), which doubled in the past month, from 3 to 6 cents, and now again hovers between 6 and 7 cents. AMBS was moving higher on the June promotions, but slid down once the emails stopped.
And Elite Pharmaceuticals, Inc. (OTCBB:ELTP) started off quite well, only to slide by around a third on selling in the past two days. ELTP also had a promising lineup of potentially viable sales- but those would only materialize long after the market was tired to support the stock’s steep climb.
If you still need to wait for a favorable court decision, it is best to keep in mind that DECN is not immune to similar sharp corrections. Avoid investing unaffordable sums, no matter how positive the potential of DECN sounds.
